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Szilvia Ráti1, Áron Zsigmond3, György Hegyi1, Zsolt Lenkei4, Máté Varga3 &  
András Málnási-Csizmadia1,5,6
Blebbistatin is a commonly used molecular tool for the specific inhibition of various myosin II 
isoforms both in vitro and in vivo. Despite its popularity, the use of blebbistatin is hindered by its poor 
water-solubility (below 10 micromolar in aqueous buffer) and blue-light sensitivity, resulting in the 
photoconversion of the molecule, causing severe cellular phototoxicity in addition to its cytotoxicity. 
Furthermore, blebbistatin forms insoluble aggregates in water-based media above 10 micromolar 
with extremely high fluorescence and also high adherence to different types of surfaces, which 
biases its experimental usage. Here, we report a highly soluble (440 micromolar in aqueous buffer), 
non-fluorescent and photostable C15 amino-substituted derivative of blebbistatin, called para-
aminoblebbistatin. Importantly, it is neither photo- nor cytotoxic, as demonstrated on HeLa cells and 
zebrafish embryos. Additionally, para-aminoblebbistatin bears similar myosin II inhibitory properties 
to blebbistatin or para-nitroblebbistatin (not to be confused with the C7 substituted nitroblebbistatin), 
tested on rabbit skeletal muscle myosin S1 and on M2 and HeLa cells. Due to its drastically improved 
solubility and photochemical feature, as well as lack of photo- or cytotoxicity, para-aminoblebbistatin 
may become a feasible replacement for blebbistatin, especially at applications when high 
concentrations of the inhibitor or blue light irradiation is required.
Blebbistatin1 is a widely used and well-characterized small molecular inhibitor of class II myosins, a group of ATP 
driven molecular motors acting in concert with actin to form a contracting actomyosin network. Myosin IIs are 
responsible for various cellular and physiological functions such as muscle contraction, cytokinesis, differentia-
tion, polarization, cell motility and blebbing2,3. Since blebbistatin blocks myosin heads in a low actin-affinity state, 
it prevents the formation of strongly-bound non-functional actomyosin complexes, which make blebbistatin a 
useful tool in the study of muscle physiology and cellular actomyosin networks4,5.
Despite its popularity, blebbistatin has several disadvantageous chemical properties, such as photoinsta-
bility, cyto- and phototoxicity, high fluorescence and very poor water solubility as above 10 μM concentration 
its slow precipitation can be observed6–9. Since the myosin inhibitory constants of blebbistatin are in a similar 
range as its solubility, this property may significantly affect the apparent experimental results. Additionally, the 
high fluorescence of blebbistatin and poor water solubility results in fluorescent aggregates which can become 
serious obstacles in light scattering or GFP-based experiments or may damage the vascular system of model 
animals10,11. Furthermore, due to the blue light sensitivity of blebbistatin, irradiation below 500 nm results in 
the photoconversion of the molecule, accompanied by the generation of reactive oxygen species responsible 
for the phototoxic effect6,7,9. As a result, irradiation or imaging human cells or animal model systems below 
500 nm in the presence of blebbistatin severely damages the samples8,9,12,13. Blebbistatin exerts cytotoxicity even 
without irradiation in long-term experiments8,9. Therefore, a non-fluorescent, photostable, non-cytotoxic and 
non-phototoxic derivative of blebbistatin has been developed recently, named para-nitroblebbistatin, which con-
tains an electron-withdrawing nitro group at the C15 (para) position8. We note that para-nitroblebbistatin is 
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a highly specific inhibitor in contrast with the C7 nitro substituted blebbistatin derivative (commonly called 
nitroblebbistatin) which exerts relatively low affinity to myosin II (IC50 = 27.5 μM) . Importantly, the in vitro and 
in vivo myosin II inhibitory properties of para-nitroblebbistatin are not affected by the nitro substitution. Despite 
its highly advantageous properties over blebbistatin, the poor water solubility of para-nitroblebbistatin, similarly 
to blebbistatin, may still restrict its application.
Blebbistatin inhibits the actin-activated ATPase activity of rabbit skeletal, porcine cardiac and scallop striated 
myosins, vertebrate non-muscle myosin lls and Dictyostelium discoideum myosin II with an IC50 of 0.5–5 μM14. 
On the other hand, the inhibition of the actin activated ATPase activity of smooth muscle and Acanthamoeba 
myosin II requires much higher blebbistatin concentrations (IC50 of 79.6 and 83 μM, respectively). Regardless 
of IC50 values and blebbistatin’s limited solubility (from 7 to 20 μM, depending on the conditions of the meas-
urements)8,15, the inhibitor is usually applied at the concentration of 50–100 μM. At such high concentrations, 
slow precipitation of blebbistatin occurs at the time-scale of hours. Therefore, the application of blebbistatin at 
higher concentrations than its solubility faces several hurdles in long-term experiments: I) the concentration of 
the inhibitor decreases over time, and so does its inhibitory effect, II) the light scattering of the media gradually 
increases, confounding/perturbing light-scattering based measurements, III) the precipitated aggregates have 
high fluorescence hampering imaging, IV) the aggregates can block the vascular system of animals in in vivo 
studies10. Furthermore, since the aggregates re-dissolve very slowly and have the tendency to attach to different 
surfaces10, complete blebbistatin wash-out from in vitro and in vivo samples is rather problematic. Such features 
resulting from the low solubility of blebbistatin in aqueous media hinders its general usage and biases its reversi-
bility in many experimental setups.
The electron withdrawing nitro substitution at the C15 position diminishes blebbistatin’s cyto- and pho-
totoxicity, reduces its fluorescence and increases its photostability8. Based on these observations we specu-
lated that substituting a polar, electron withdrawing group at this position may not only offer the benefits of 
para-nitroblebbistatin but would also elevate the water solubility of the new derivative. Based on this assumption, 
we synthesized para-aminoblebbistatin, whose protonated amino group at physiological pH provides the desired 
positive charge and a strong electron withdrawing characteristic. We also present the in vitro and in vivo myosin II 
inhibitory features of para-aminoblebbistatin on several different myosin isoforms. Importantly, we demonstrate 
that the new derivative of blebbistatin is non-fluorescent, photostable, non-cytotoxic, non-phototoxic while its 
solubility is more than 40x higher than blebbistatin’s or para-nitroblebbistatin’s. Para-aminoblebbistatin forms a 
stable solution in aqueous buffers and does not precipitate.
Results
Synthesis of para-aminoblebbistatin. We have demonstrated that the C15 position of blebbistatin can 
be modified without affecting its myosin II inhibitory properties8,15. Electron withdrawing substitutions at this 
position – such as chloro or nitro groups – not only quench the fluorescence of blebbistatin but also elevate its 
photostability. Furthermore, C15 nitro substitution eliminates both the blue light phototoxicity and the cyto-
toxicity of blebbistatin. In order to get a photostable, non-fluorescent and a highly soluble blebbistatin deriva-
tive we synthesized its C15 amino-substituted form. Para-aminoblebbistatin was synthesized by the reduction 
of para-nitroblebbistatin in the presence of ammonium formate using palladium black catalyst (Fig. 1). Para-
nitroblebbistatin was synthesized according to published protocols8.
Physico-chemical characterization of para-aminoblebbistatin. We measured the solubility and 
solution stability of para-aminoblebbistatin, para-nitroblebbistatin and blebbistatin in 0.1 and 1 vol/vol% DMSO 
at room temperature. 50 μM of the inhibitors were dissolved in assay buffer (see Experimental Procedures) con-
taining 0.1 or 1 vol/vol% DMSO, centrifuged at the indicated times and the concentration of the supernatants 
were determined at each time point (Fig. 2a,b). In two hours blebbistatin and para-nitroblebbistatin solutions 
reached equilibrium, yielding solubility values of 10.9 ± 0.9 μM and 3.3 ± 0.1 μM in 0.1 vol/vol% DMSO and 
9.3 ± 0.7 μM and 3.6 ± 0.2 μM in 1 vol/vol% DMSO, respectively (enlarged in the insets of Fig. 2a,b). 50 μM 
para-aminoblebbistatin stayed stable in solution during the whole experiment in both 0.1 and 1 vol/vol% DMSO. 
Tha saturation concentrations for para-aminoblebbistatin were determined as 298 ± 2.5 μM and 426 ± 1.7 μM in 
0.1 vol/vol% DMSO and 1 vol/vol% DMSO respectively (Fig. 2a,b). At these concentrations, the solutions were 
stable even for several days.
Blebbistatin has high fluorescence with an emission peak at 410 nm, which can be a serious disadvantage 
in fluorescence-based experiments. In contrast, para-aminoblebbistatin, similarly to para-nitroblebbistatin, 
is non-fluorescent due to the electron withdrawing substitution at the C15 position (Fig. 2c). Besides its 
high fluorescence blebbistatin is also photodegradable and can be photo-inactivated, which is accompanied 
by the alteration of its absorbance spectra reflecting changes in its molecular structure6,9,16. We compared 
para-aminoblebbistatin’s photostability to blebbistatin’s by irradiating the molecules in assay buffer at 480 ± 10 nm 
for different lengths of time (which is a typical GFP excitation range) and recorded the absorption spectra after-
wards (Fig. 2d). The spectra of blebbistatin changed markedly indicating photo-induced changes in the molecular 
structure, consistent with previously published results (inset of Fig. 2d). In contrast, absorption spectrum of the 
para-aminoblebbistatin solution have not altered considerably, demonstrating significantly improved photosta-
bility, similarly to para-nitroblebbistatin8.
In vitro and in vivo inhibitory properties of para-aminoblebbistatin. After the physico-chemical 
characterization of para-aminoblebbistatin, we compared its in vitro and in vivo inhibitory properties to those 
of blebbistatin and para-nitroblebbistatin. We measured the basal and actin activated ATPase activites of rabbit 
skeletal muscle myosin S1 (SkS1) and Dictyostelium discoideum myosin II motor domain (DdMD) at increasing 
concentrations of para-aminoblebbistatin, para-nitroblebbistatin or blebbistatin (Fig. 3a,b). All three myosin II 
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Figure 1. Synthesis of para-aminoblebbistatin. Reagents and conditions: (a) H2SO4, HNO3, 0 °C, 15 min;  
(b) POCl3, CH2Cl2, 50 °C, 18 hours; (c) LiHMDS, −78 °C to 0 °C, 3 hours; (d) oxaziridine, −10 °C, 16 hours;  
(e) NH4HCO2, Pd black, CH3OH, RT, 18 hours.
Figure 2. Physico-chemical properties of para-aminoblebbistatin (AmBleb), para-nitroblebistatin 
(NBleb) and blebbistatin (Bleb). (a) Solubility of AmBleb, NBleb and Bleb in 0.1 vol/vol% DMSO in assay 
buffer in time. After the centrifugation of a 500 μM of AmBleb suspension in assay buffer yielded 298 ± 2.5 μM 
soluble supernatant concentration. The concentration of this solution stayed constant for 4 hours. Supernatant 
concentrations of 50 μM of NBleb and Bleb decreased exponentially after centrifugation at different lengths of 
time (enlarged in the inset), reaching equilibria at 3.3 ± 0.1 μM and 10.9 ± 0.9 μM, respectively (obtained from 
fitting the data to single exponential functions). (b) Solubility of AmBleb, NBleb and Bleb in 1 vol/vol% DMSO 
are 426 ± 1.7 μM, 3.6 ± 0.2 μM and 9.3 ± 0.7 μM, respectively (enlarged in the inset, obtained from the exponential 
fits to data). (c) Fluorescence spectra of AmBleb, NBleb and Bleb at λexc = 350 nm. (d) Absorbance spectra of 
AmBleb and Bleb (inset) after irradiating 5 μM of the inhibitors at 480 ± 10 nm for different lengths of time.
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inhibitors decreased the basal as well as actin activated ATPase activity of SkS1 to a maximal extent (~98–100%) 
yielding half-maximal inhibitory concentration values of IC50,AmBleb = 1.3 ± 0.1 μM, IC50,NBleb = 0.3 ± 0.04 μM and 
IC50,Bleb = 0.3 ± 0.03 μM for the basal ATPase of SkS1 and IC50,AmBleb = 0.47 ± 0.06 μM, IC50,NBleb = 0.1 ± 0.004 μM 
and IC50,Bleb = 0.11 ± 0.009 μM for the actin activated ATPase activity of SkS1. Para-nitroblebbistatin and bleb-
bistatin also exerted maximal inhibition on DdMD (~100%), while AmBleb reached 90% and 80% inhibition 
on basal and actin activated ATPase activities of DdMD yielding half-maximal inhibitory concentration val-
ues of IC50,AmBleb = 6.6 ± 2 μM, IC50,NBleb = 5.3 ± 1.6 μM and IC50,Bleb = 4.4 ± 0.3 μM for the basal ATPase and 
IC50,AmBleb = 6.7 ± 1.9 μM, IC50,NBleb = 3.4 ± 0.3 μM and IC50,Bleb = 3.9 ± 0.3 μM for the actin activated ATPase 
activity of DdMD. It should be noted that IC50 of AmBleb is higher by 4.3 and 1.7 times on SkS1 and DdMD, 
respectively.
Next, we compared the non-muscle myosin II inhibition by para-aminoblebbistatin, para-nitroblebbistatin 
and blebbistatin in human melanoma (M2) and HeLa cells. As blebbistatin acquired its name from its ability to 
block blebbing of M2 cells1, we compared blebbing indices17 of M2 cells in time, incubated in the three different 
myosin II inhibitors at different concentrations (Fig. 3c–e). Even 5 μM concentrations of the myosin II inhibitors 
achieved significant decrease in the blebbing indices of the cells within an hour, whereas higher concentrations of 
the inhibitors completely stopped blebbing of the cells within >40–60 minutes (10 μM) or >20 minutes (25 and 
50 μM). The rate constants for the inhibition of blebbing of M2 cells at 5 μM inhibitor concentrations were similar, 
whereas at 10 and 25 μM concentration of para-aminoblebbistatin the rate constants were slightly slower than 
those of para-nitroblebbistatin or blebbistatin (Table 1).
Blebbistatin also inhibits or enhances motility of different cell lines on different substrates and on 2D or 3D 
environments18,19, and seems to moderately enhance the motility of HeLa cells on 2D surfaces (~140% compared 
to 100% of the control)19. To test the effect of the different myosin II inhibitors on the motility of HeLa cells on 
uncoated glass surface, we carried out wound-healing assays in the absence and in the presence of 20 μM con-
centrations of the inhibitors (Fig. 4f). All three inhibitors increased motility of HeLa cells compared to untreated 
cells, quantified after 24 hours of incubation (30.6 ± 5.4% for control, 62.6 ± 3.6% for AmBleb, 53.2 ± 17.6% for 
NBleb and 51.4 ± 4.7% for Bleb, where 100% is considered as the total diameter of the wound).
Another important feature of blebbistatin and para-nitroblebbistatin is that they block cytokinesis and induce 
multinucleated cells through the inhibition of non-muscle myosin II, thereby keeping low cell number in human 
cancer cell cultures1. Therefore, we followed cell number of HeLa cells in time at different inhibitor concentrations 
of para-aminoblebbistatin and compared the results to those of para-nitroblebbistatin- and blebbistatin-treated 
cells (Fig. 3g). Cells incubated in different concentrations of the inhibitors were counted on each day for three 
days. On the 3rd day of the experiment, cell number in the absence of inhibitors (0 μM) increased to 3–3.5 times 
of the initial cell number, whereas 25 or 50 μM of the inhibitors completely inhibited cytokinesis resulting in no 
significant increase in cell number. The IC50 values of the inhibition of cell proliferation (Fig. 3h) were similar in 
the case of para-aminoblebbistatin and para-nitroblebbistatin (IC50,AmB = 17.8 ± 4.7 μM, IC50,NB = 14.7 ± 4.2 μM) 
but 2–3 times weaker than blebbistatin’s (IC50,B = 6.4 ± 4.8 μM).
Since the myosin II inhibitors decrease the ATPase activity of SkS1 in vitro, we tested their inhibition on 
zebrafish skeletal muscle in vivo. We investigated the fast escape response (C-start) reflex of 6 dpf fish evoked by 
standardized tapping stimuli (Video 1). First, the head of the zebrafish embryo rotates about the center of mass 
towards the direction of future escape, then the body exhibits a curvature that resembles a letter C, mediated 
by quick contraction of the muscles on one side accompanied by relaxation on the other side20. The velocity of 
the rotating heads of the embryos were quantified (maximal angular velocity) in the absence and in the pres-
ence of increasing concentrations of the myosin II inhibitors (2, 5, 10, 20 μM), monitored for 4 hours. The half 
maximal effective concentration (EC50) values for the inhibition of the maximal angular velocity by the myosin 
II inhibitors are below 2 μM since even at 2 μM the inhibitory effects were >90% for all inhibitors . We experi-
enced that the inhibitory effect of para-aminoblebbistatin is exerted much slower than that of blebbistatin and 
para-nitroblebbistatin, probably due to its slower uptake (half inhibitions at 0.6, 1.3 and 3.2 hours, respectively) 
(Supplementary Figure 1). To further evaluate the specificity of blebbistatin and its derivatives on different myo-
sin II isoforms, we examined the effect of the inhibitors on 6 dpf (days post fertilization) zebrafish heart muscle 
in vivo. We monitored heart beating and the amplitude of heart muscle contraction before and after the addition 
of 20 μM of the inhibitors to the specimens. By the addition of the inhibitors the pulse rate (heart beats/time) did 
not change substantially in the first three hours (between 120 and 130 beats/minute). In contrast, the amplitude 
of contraction and consequently the blood circulation dropped drastically within the first hour in blebbistatin and 
para-nitroblebbistatin and within three hours in para-aminoblebbistatin (Video 2).
Enhanced imaging by the non-phototoxic and non-cytotoxic para-aminoblebbistatin. The 
blue light phototoxicity of blebbistatin is one of its most annoying limitations, which makes live-cell fluores-
cence microscopy unfeasible applying blue light excitations. To test the applicability of para-aminoblebbistatin 
in live-cell fluorescence microscopy, we time-lapse imaged EGFP-α-tubulin H2B-mCherry labeled HeLa Kyoto 
cells in a confocal microscope (Fig. 4a). Cells were treated with 50 μM para-aminoblebbistatin or blebbistatin 
and imaged for 12 hours applying 3 z-sections every 10 minutes. Cells receiving para-aminoblebbistatin treat-
ment did not show any sign of phototoxicity, while numerous blebbistatin-treated cells rounded up from the 
surface and eventually died within a few hours of imaging. This was accompanied by their increased autofluores-
cence and fragmented, dense nuclei (increased green fluorescence of cytoplasm and red fluorescence of nuclei, 
co-localizing as yellow, an example marked by a white arrowhead in Fig. 4a). Additionally, microscopic images 
of blebbistatin-treated cells were highly disturbed by the fluorescent precipitates of blebbistatin formed at this 
concentration.
In live zebrafish embryo tests, myosin II inhibition by blebbistatin proved to be highly toxic after 24 hours of 
incubation, whereas using para-nitroblebbistatin the cytotoxic effect was negligible8. In order to compare the 
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Figure 3. In vitro and in vivo inhibitory properties of para-aminoblebbistatin, para-nitroblebbistatin and 
blebbistatin. In vitro inhibition of basal (a) and actin activated (b) ATPase activity of rabbit skeletal S1 (SkS1) 
and Dictyostelium discoideum myosin II motor domain (DdMD) at increasing concentrations of AmBleb, NBleb 
and Bleb. Data (means ± s.d. from three independent experiments) were normalized to ATPase activities at 
0 μM inhibitor concentrations and were fitted with hyperbolic functions. (c–e) Blebbing indices of M2 cells 
in the presence of increasing concentrations of AmBleb (c), NBleb (d) and Bleb (e) monitored for 60 minutes. 
Blebbing indices are means and standard deviations/means and s.d./means ± s.d. (n = 6) of the number of 
blebs formed in a 5-minute interval on a cell17. Blebbing index values are normalized to the starting point. Data 
were fitted with exponentials yielding rate constants of inhibition for 5, 10, 25 and 50 μM of the inhibitors (see 
Table 1.) (f) Relative migration of HeLa cells measured after 24 h in the absence (Control) or in the presence 
of 20 μM AmBleb, NBleb and Bleb (left panel). 100% is considered as the total diameter of the wound (n = 6 
scratches, from two independent experiments). Representative images of wound healing assays immediately after 
scratching (0 min) and after 24 h incubation with AmBleb or without the inhibitors (Control). White lines mark the 
cell edges at 0 minutes (g). Inhibition of cell number growth of HeLa cells by increasing concentrations of AmBleb, 
NBleb and Bleb monitored for three days. Cell numbers were normalized to 0 μM inhibitor concentrations counted 
on the first day of the experiment. (h) Cell number as a function of increasing inhibitor concentrations at day 3 of 
the experiment presented in (g). Data (means ± s.d., n = 50–100) were fitted with hyperboles.
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cyototoxicity of para-aminoblebbistatin to that of blebbistatin, we treated zebrafish embryos with the inhibitors 
at different concentrations and followed their development for 72 hours and determined their lifespan (Fig. 4b). 
After 40 hours, blebbistatin-treated zebrafish embryos started to die, and at 69 hours all of them died at all bleb-
bistatin concentrations. In contrast, embryos treated with para-aminoblebbistatin did not show any sign of cyto-
toxicity even at high concentrations and their fitness was comparable to the untreated control embryos.
Multinuclearity of the inhibitor-treated HeLa cells can be demonstrated well on the 3rd day of incubation in the 
presence of 50 μM para-aminoblebbistatin, para-nitroblebbistatin or blebbistatin from the experiment presented 
in Fig. 3e,f (Fig. 4c). However, the highly fluorescent, dense precipitates of blebbistatin disturb imaging in the GFP 
channel of the microscope. Since para-aminoblebbistatin is soluble at this concentration, it does not form aggre-
gates. Although para-nitroblebbistatin is not soluble at 50 μM concentration, the aggregates are not fluorescent 
using 488 nm excitation by confocal micrsocopy, thus they do not affect imaging. Interestingly, using 470 ± 20 nm 
excitation by an epifluorescent microscope, the aggregates of para-nitroblebbistatin are visible and also disturb 
imaging, while blebbistatin aggregates in this case completely hindered the observation of the GFP signal. In this 
experiment, cldnb:gfp zebrafish embryos were imaged by an epifluorescent microscope after 24 hours of incu-
bation in the presence of 20 μM concentrations of the indicated inhibitors (Fig. 4d) in order to detect the effect 
Concentration
5 μM  
τ (min)
10 μM 
τ (min)
25 μM 
τ (min)
50 μM 
τ (min)
Bleb 24.6 ± 2 10.5 ± 0.8 5.4 ± 1 –
NBleb 21.9 ± 4.6 11.7 ± 0.5 5.9 ± 0.2 –
AmBleb 25.0 ± 4.3 16.8 ± 1.6 9.9 ± 0.3 7.8 ± 0.3
Table 1. Inhibition of blebbing of M2 cells. Time constant (τ) ± s.d. values of inhibition of blebbing are 
determined from the fitted exponentials to data of Fig. 3b–d.
Figure 4. Phototoxicity and cytotoxicity assays with para-aminoblebbistatin or blebbistatin and 
fluorescent imaging in the presence of the myosin II specific inhibitors. (a) Maximum intensity projections 
of fluorescent confocal microscopic z-stack images of EGFP-α-tubulin H2B-mCherry HeLa Kyoto cells at the 
beginning and at the end of a 12-hour time-lapse imaging in the presence of 50 μM AmBleb or Bleb. Blebbistatin 
treated cells display severe phototoxicity (white arrowhead). (b) Lifespan cytotoxicity assays of zebrafish 
embryos (n = 20) incubated at increasing concentrations of AmBleb and Bleb (inset) in dark. (c) Fluorescent 
confocal microscopic images of HeLa Kyoto cells in the presence of 50 μM inhibitor concentrations on the 3rd 
day of the experiment presented in Fig. 3e,f. (d) 48 hpf (hours-post-fertilization) cldnb:EGFP zebrafish embryos 
in the absence (Control) and in the presence of 20 μM of the myosin II inhibitors after 24 hours of incubation. 
Red arrowheads mark the position of the pLLps.
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of myosin II inhibition on the proliferating leading edge of the posterior lateral line primordium (pLLp)21 and 
visualize the effect of the precipitates by epifluorescent microcopy. Similarly to para-nitroblebbistatin and bleb-
bistatin, para-aminoblebbistatin also halted pLLp migration, indicating in vivo myosin II inhibition4,8,22. In the 
case of para-aminoblebbistatin treatment, the GFP signal of the migrating pLLp can be visualized clearly, while 
the precipitates of the two other inhibitors highly disturbed the imaging.
Discussion
Blebbistatin is the most commonly used myosin II inhibitor, but its applicability is greatly hampered by its low 
solubility as well its sensitivity to blue light. In the majority of the published studies, blebbistatin is applied at 
50–100 μM concentrations, although at such concentrations blebbistatin precipitates and the effective concentra-
tion exponentially drops to the equilibrium saturation concentration (9 μM) in two hours. Since the precipitated 
aggregates have the propensity of attaching to surfaces like the wall of the Eppendorf tube or the pipette, the 
actual concentration of the inhibitor becomes uncertain during the experimental procedures. This effect signifi-
cantly decreases the reproducibility of the studies and causes serious problems for researchers. Furthermore, the 
solubility saturation concentration of blebbistatin is often in the similar range as the EC50 of its myosin II inhibi-
tion, consequently, most of these myosin II molecules cannot be saturated with blebbistatin in aqueous buffers.
According to our experience and other published studies, increasing blebbistatin concentrations to higher 
values than its solubility was accompanied by an increased inhibitory effect as well. In order to resolve this dis-
crepancy, we followed the precipitation kinetics of blebbistatin and found that its initial apparent solubility in fact 
can be much higher than its saturation concentration. Thus, a freshly prepared blebbistatin sample can reach even 
50 μM before it drops to its half concentration in <20 minutes. Further complications may arise from the uncer-
tainty of blebbistatin’s actual concentrations in membranes and within cells. Additionally, low actual concentra-
tions cause significant time delays in myosin II inhibition after blebbistatin addition both in vitro and in vivo. 
As an example, the on-rate constant of blebbistatin for binding to rabbit skeletal muscle myosin II is relatively 
low (kon = 0.0034 μM−1 s−1)5. Therefore, it requires more than a minute for 10 μM of blebbistatin to bind to 90% 
of rabbit skeletal myosin, even though this myosin isoform is among the strongest blebbistatin binders within 
myosin IIs. Thus, for a more rapid inhibition, much higher blebbistatin concentrations may be applied. Further 
difficulties may rise during in vitro light scattering or fluorescent spectroscopic measurements as well due to the 
precipitation of blebbistatin.
All issues described above can be overcome by the use of para-aminoblebbistatin, because it is highly solu-
ble and forms stable solutions even at over 100 μM concentrations. Additionally, it is non-fluorescent both in 
its unbound form and in complex with proteins. Para-aminoblebbistatin is specific to skeletal muscle myosin 
in vitro and in vivo, heart muscle myosin in vivo, Dictyostelium myosin II and non-muscle myosin IIs, although its 
binding constants are slightly lower compared to blebbistatin or para-nitroblebbistatin. Further important advan-
tages of para-aminoblebbistatin over blebbistatin are its low phototoxicity and cytotoxicity, which are similar to 
those of para-nitroblebbistatin. Additionally, both para-aminoblebbistatin and para-nitroblebbistatin are highly 
photostable, which may be an important feature in different experimental setups where continuous blue-light 
irradiation is applied. Since blebbistatin degrades relatively rapidly under blue light, its activity decreases quickly 
biasing its actual concentration.
In summary, para-aminoblebbistatin is a useful replacement of blebbistatin in myosin II inhibition experi-
ments. Para-aminoblebbistatin provides a great advantage when high concentration of the inhibitor is required, 
cytotoxic or phototoxic effects cause difficulties or fluorescence imaging would be disturbed by blebbistatin.
Methods
Synthesis of para-aminoblebbistatin. 3.6 mg para-nitroblebbistatin (synthesized as in8) was dissolved 
in 0.7 ml methanol and it was mixed with 0.7 ml cc. ammonium formate in methanol solution. A few granules of 
palladium black were added and the mixture was stirred for 18 hours at room temperature. A Strata XL 2g SPA 
column (Phenomenex) was equilibrated with 50 ml acetonitrile, then 50 ml water and the crude reaction mixture 
was pipetted onto the column. It was sequentially washed with 20 ml water, then eluted with 20 ml acetonitrile 
containing 1% trifluoroacetic acid and dried in vacuum. The brownish oil was dissolved in 0.5 ml acetonitril 
containing 0.1% triethylamine (TEA). The product was isolated by HPLC (Agilent 1100 instrument) using Luna 
250 × 10 mm C18(2) column (Phenomonex). The HPLC conditions were as follows: isocratic elution, content of 
buffer: water (0.1% TEA): acetonitrile (0.1% TEA) = 3:7, flow rate: 3, 5 ml/min, detection wavelength: 254 nm. Ms 
(ESI): m/z = 308.1 [M + H]+. Chemical purity: consistent with >95% purity (LC, 210 nm). Appearance: orange 
solid.
Solubility assays. 500 μM para-aminoblebbistatin and 50–50 μM para-nitroblebbistatin and blebbistatin 
solutions were prepared in assay buffer (40 mM NaCl, 4 mM MgCl2, 20 mM HEPES pH 7.3). The DMSO content 
was 1%. After 0, 5, 25, 60 and 240 minutes, the samples were centrifuged at 13,000 g for 1 minute. Absorption 
spectra of the supernatants were recorded and the concentrations of the dissolved inhibitors were determined 
using the following extinction coefficients: para-aminoblebbistatin (ε°427 = 6860 M−1cm−1), blebbistatin 
(ε°427 = 6100 M−1cm−1), para-nitroblebbistatin (ε°427 = 11175 M−1cm−1). The experiments were repeated three 
times.
Conditions of spectral measurements. Fluorescence emission spectra (λexc = 350 nm) were recorded 
in assay buffer containing 0.1% DMSO applying the inhibitors at 5 μM concentrations. The photoconversion 
measurements were carried out using 5 μM para-aminoblebbistatin or blebbistatin in assay buffer and irradiat-
ing the samples at 480 ± 10 nm for 0, 5, 10 and 15 minutes using a Fluorescence Spectrometer (F900, Edinburgh 
Instruments) equipped with a 450 W Xenon Lamp. Their absorbance spectra were measured at each time point.
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Steady state ATPase measurements. MgATPase activities of 500 nM (for basal ATPase) or 50 nM (for 
actin activated ATPase) SkS1 (rabbit skeletal S1 fragment)23 and 1 μM (for basal ATPase) or 300 nM (for actin 
activated ATPase) DdMD were measured at increasing concentrations of blebbistatin, para-nitroblebbistatin or 
para-aminoblebbistatin in the absence or in the presence of 45 μM actin for SkS1 or 15 μM actin for DdMD. 
Measurements were carried out using a pyruvate kinase/lactate dehydrogenase coupled assay (NADH-coupled 
assay) [5] at 25 °C or 20 °C in case of SkS1 or DdMD, respectively. Myosin and actin together with the indicated 
concentration of the inhibitor were pre-incubated for 5 minutes at room temperature and the measurements 
were initiated with 1 mM ATP. Data were corrected for background ATPase activity of actin. G-actin was pre-
pared accordingly from rabbit skeletal muscle24 and polymerized by 2 mM MgCl2 for 1 hour at room temperature. 
Measurements were performed in low salt buffer containing 5 mM HEPES, 2 mM MgCl2, 0.1 mM EGTA and 
2 mM DTT at pH 7.2 or assay buffer containing 20 mM HEPES, 40 mM NaCl, 4 mM MgCl2 at pH 7.3 for basal 
ATPase activity measurements with DdMD.
Cell culture maintenance. HeLa Kyoto H2B-mCherry eGFP-α-tubulin cells were purchased from Cell 
Lines Service GmbH and maintained in DMEM high glucose (4.5 g/L) supplemented with 10% FBS, 2 mM 
L-glutamine, 100 U/ml streptomycin, 100 μg/ml penicillin, 0.5 mg/ml G418 and 0.5 μg/ml puromycin. HeLa cells 
were a kind gift from Sára Tóth (Semmelweis University, Faculty of Medicine, Department of Genetics, Cell- 
and Immunobiology) and were maintained in low glucose DMEM (1 g/l) supplemented with 10% FBS, 2 mM 
L-glutamine, 100 U/ml streptomycin and 100 μg/ml penicillin. M2 cells ‒ a kind gift of Tom Stossel and Fumihiko 
Nakamura (Brigham & Women’s Hospital, Harvard Medical School, Translational Medicine Division) ‒ were 
grown in MEM (Lonza) supplemented with 8% newborn calf serum (Sigma) and 2% FCS. The cell cultures were 
maintained in a humidified atmosphere of 5% CO2 at 37 °C. Cells were grown as monolayers in T-75 cm2 culture 
flasks and subcultured by 0.02% EDTA (200 mg/l) 2–3 times each week when reached 90% confluency.
Conditions of cellular assays. For blebbing index determination, M2 cells were incubated for 30 minutes 
in PBS in every case prior to the addition of inhibitors, in order to initiate extensive blebbing. Blebbing of the 
cells was monitored before as well as after inhibitor addition to the cells. DMSO concentration was 0.1 vol/vol% 
in all experiments. Blebbing index was calculated by summing the initiated blebs in a 5-minute interval (starting 
at the indicated time points) on a given standard area17 (whole cells with similar size, diameter = 12 ± 1 μm) and 
normalizing it to the blebbing index prior to inhibitor treatment.
For wound healing assays, 200 μl of HeLa cells were plated on 35 mm borosilicate glass imaging dishes at 
300,000 cells/ml concentrations and incubated for 24 hours. 1 hour prior to wounding, cells were incubated in 
20 μM of the different myosin II inhibitors. After one hour, scratches were made with pipette tips in monolayer 
cultures and the motility of cells for occupying the wound was monitored for 24 hours with a Foculus Digital 
Camera (IEEE1394). Analysis of cell motility was carried out by ImageJ, by measuring the distance between two 
lines fitted on the two sides of the approaching cell edges created by the pipette tips.
For cell growth assays, HeLa Kyoto H2B-mCherry eGFP-α-tubulin cells were grown on an eight-chambered 
Lab-Tek borosilicate cover glass system, with the initial cell concentration of 100,000 cells/ml. As soon as the cells 
attached to the surface, they were treated with 0, 2, 5, 10, 25 or 50 μM concentrations of para-amino-, para-nitro- 
or blebbistatin. Cells were grown for three days in the presence of the indicated inhibitor concentrations and cell 
numbers were quantified each day. The final vol/vol% of DMSO in all experiments was 0.1. Data analysis was 
carried out by Fiji software. On the third day of the experiment, multinuclear cells were visualized by using a 
Zeiss LSM 710 with a Plan Apo 20x/0.8 objective. For phototoxicity experiments, confocal time-lapse imaging of 
HeLa Kyoto H2B-mCherry eGFP-α-tubulin cells for 12 hours was performed in DMEM further supplemented 
with 25 mM HEPES in order to achieve CO2-independent media. Confocal time-lapse imaging was performed 
on a Zeiss LSM 710 using a Plan Apo 20x/0.8 objective, with the following parameters: 2% laser intensity at 
λexc = 488 nm, 3% laser intensity at λexc = 543 nm, 1.2× zoom, average 4, line step 1, 1000 × 1000 pixels, 0.35 μm 
pixel size, 0.65 μs dwell time, 3 slice/z-stack with 7 μm between slices at every 10 minutes.
Fish husbandry and embryo treatments. Transgenic Tg(−8.0cldnb:lynEGFP)zf106 (cldnb:EGFP)25 zebraf-
ish (Danio rerio) were maintained in the animal facility of Eötvös Loránd University. For the experiments investi-
gating the skeletal and heart muscle of zebrafish, 6 dpf embryos were used. For cytotoxicity assays, 2 dpf embryos 
were dechorionated and placed in the indicated reagent concentrations. Embryos were kept in E3 medium (5 mM 
NaCl, 0.33 mM MgCl2, 0.33 mM CaCl2 and 0.17 mM KCl).
Conditions of assays with zebrafish embryos. For the fast escape response experiments, 6 dpf embryos 
were placed in 50 μl drops of E3 medium on a plastic plate. They were treated with 0, 2, 5, 10 or 20 μM of the 
inhibitors. 10 taps were carried out with 1 minute intervals every hour for 4 hours. The tapping force was stand-
ardized. The videos were recorded by a Ximea Camera (MQ003MG-CM) at 500 fps for 2 s. Data were analyzed 
by Flote software version 2.1 and maximal angular velocity parameters of C-start reflex were quantified. For the 
experiments investigating the effect of the inhibitors on the heart muscle of zebrafish, 6 dpf larvae were embed-
ded in 1% agarose and kept in E3 in the presence of 20 μM concentrations of the inhibitors. Videos were taken at 
15.1 fps before and after inhibitor treatment every hour for 3 hours. For the cytotoxicity assay, zebrafish embryos 
were incubated in E3 medium containing 0 μM (Control), 5 μM, 10 μM or 20 μM of para-aminoblebbistatin, 
para-nitroblebbistatin or blebbistatin in 0.1 vol/vol% final concentration of DMSO and monitored for 70 hours. 
Embryos were considered to be dead when the whole body became necrotic and the heart stopped beating. Dead 
embryos were removed from the experiment to prevent contamination. Images of zebrafish were captured with a 
Zeiss Stereo Lumar V12 microscope using a NeoLumar S 0.8x FWD 80mm objective at 50× zoom.
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All experiments were performed in accordance with relevant guidelines and regulations approved by the 
Hungarian National Food Chain Safety Office (Permit Number: XIV-I-001/515-4/2012).
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